July 19, 2019
Arrowhead Pharmaceuticals, led by CEO Christopher Anzalone, is testing RNA molecular technology to treat genetic diseases.
Stories this photo appears in:
Health Care: Arrowhead and Prospect Medical could give sector a shot in the arm
The Los Angeles health care market has seen a trend toward fewer but bigger deals in the last few years, and 2020 could bring more of the same.
Two companies appear to be heading in opposite directions this year in the biomed and health care space.
Pasadena biotech firm Arrowhead Pharmaceuticals Inc. set an offering of 4 million shares, seeking to raise up to $232 million to fund operations and strategic investments.
Arrowhead Pharmaceuticals shares surged Nov. 25 as investors reacted to positive earnings and news of a major acquisition in the pharma category.
Biggest Gainer in Rank
SPECIAL REPORT: LARGEST PUBLIC COMPANIESMarket Cap: $2.51 billion